evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

168 questions · 172 findings · 12 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 33 · 19.2%GRADE not reported 23 · 13.4%Very low 63 · 36.6%Low 37 · 21.5%Moderate 16 · 9.3%High 0 · 0%

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher adverse events: Specific ‐ prolactin‐related Reported by… compared with ORAL QUETIAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Relapse · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in global state: Relapse (any reason) ‐ long term Assessed by 5 blinded… compared with ORAL ARIPIPRAZOLE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Leaving the study early · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Adverse events: General ‐ serious Unclear how these events were reported · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General ‐ serious Unclear how these events were… compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Weight gain · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ weight increase compared with ORAL ARIPIPRAZOLE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs OLANZAPINE

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs OLANZAPINE

Adverse events: General ‐ serious · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs OLANZAPINE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs OLANZAPINE

Weight gain · patients with schizophrenia

RISPERIDONE DEPOT may leads to lower adverse events: Specific ‐ weight increase compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Mental state: PANSS responders (ITT data) ‐ medium term PANSS responders‐ participants achieving a >30% improvement in total score · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in mental state: PANSS responders (ITT data) ‐ medium term PANSS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Adverse events: Movement disorder requiring the use of anti‐EPS medication ‐ medium term · patients with schizophrenia

RISPERIDONE DEPOT probably leads to higher adverse events: Movement disorder requiring the use of anti‐EPS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review